Item 8.01. Other Events.
Evelo Biosciences, Inc. (the "Company") recently updated its business
information as follows:
Phase 2 Clinical Trial of EDP1815 in Atopic Dermatitis
On December 22, 2021, the Company announced planned updates to the study
protocol for its Phase 2 clinical trial of EDP1815 in atopic dermatitis. Based
on previously reported results from a Phase 2 clinical trial of EDP1815 in mild
and moderate psoriasis and the results from a cohort of participants with
moderate atopic dermatitis in the Company's on-going Phase 1b clinical trial of
EDP1815 in mild and moderate psoriasis and mild and moderate atopic dermatitis,
the Company has decided to increase the number of participants to 300, extend
the dosing period to 16 weeks, reduce the lowest dose to be investigated, and
evaluate EDP1815 drug substance produced using two different manufacturing
processes in the Phase 2 atopic dermatitis trial.
The primary objective of the multicenter, double-blind, placebo-controlled Phase
2 trial is to show superiority of EDP1815, dosed for 16 weeks, over placebo. The
primary endpoint will be the percent of participants who achieve a 50% reduction
in the Eczema Area and Severity Index (EASI) score (EASI-50) at week 16.
Secondary endpoints will include several physician-reported outcomes, such as
Investigator Global Assessment (IGA) and Body Surface Area (BSA), along with
patient-reported outcomes such as the Dermatology Life Quality Index, itch using
the daily Peak Pruritus Numerical Rating Scale, and Patient Oriented Eczema
Measure (POEM).
Participants will be randomized into one of three cohorts. Each cohort will
include approximately 100 participants randomized in a 3:1 ratio (75 to EDP1815
and 25 to placebo) for a total of 300 participants. Cohort 1 will explore a
daily dose of 1.6 x 1011 total cells of EDP1815 or matching placebo administered
as two capsules once daily. Cohorts 2 and 3 will explore a daily dose of 6.4 x
1011 total cells of EDP1815 or matching placebo administered as two capsules
once daily or one capsule twice daily, respectively. The different
concentrations of drug (1.6 x 1011 total cells and 6.4 x 1011 total cells) are
prepared from two different manufacturing processes.
All participants will have the opportunity to join an open label extension trial
once they complete 16 weeks of dosing. Participants in the open label extension
trial will receive EDP1815 for up to 52 weeks.
Based on these planned changes to the study protocol, it is anticipated that
dosing for the Phase 2 atopic dermatitis trial will begin in the first quarter
of 2022, with results anticipated in the first half of 2023.
Phase 1b Clinical Data with EDP1815 in Atopic Dermatitis
On December 22, 2021, the Company announced data from a cohort of 24
participants with moderate atopic dermatitis in its on-going Phase 1b clinical
trial of EDP1815 in mild and moderate psoriasis and mild and moderate atopic
dermatitis. The participants were randomized in a 2:1 ratio, with 16 receiving
EDP1815 (6.4 x 1011 total cells) and 8 receiving a matching placebo once daily
for eight weeks. The primary objective was to assess the safety and tolerability
of the higher concentration EDP1815 after eight weeks of dosing. The secondary
objective was to assess the clinical improvement in participants with moderate
atopic dermatitis. All the participants used an emollient twice daily for at
least seven consecutive days immediately prior to day 1 and continued to use the
background emollient treatment twice daily throughout the trial.
In this cohort, EDP1815 was shown to be well-tolerated with no treatment-related
adverse events of moderate or severe intensity and no serious adverse events
through eight weeks of dosing. The safety data were consistent with what
previously was seen in another Phase 1b cohort of participants with mild and
moderate atopic dermatitis, as well as in a Phase 2 clinical trial of EDP1815 in
mild and moderate psoriasis.
In this cohort, the mean percent change and proportion of responders were
evaluated after 8 weeks of dosing. An initial improvement in mean percent change
in EASI was observed at day 15 compared to placebo; however, the population mean
change decreased over the remainder of the dosing period, and there was no
overall difference from placebo at the end of the dosing period.
These results differ from previously reported results from another cohort of 24
participants with mild and moderate atopic dermatitis in the Phase 1b clinical
trial of EDP1815 (1.6 x 1011 total cells). In the earlier cohort, the data
showed consistent improvements in percentage change from baseline compared to
placebo across three clinical scores: EASI, IGA*BSA, and SCORing Atopic
Dermatitis. In addition, 7 out of 16 (44%) participants dosed with EDP1815 for 8
weeks achieved an EASI-50 by day 70, compared with 0% in the placebo group.
Given the difference in clinical effects seen between the two cohorts, which
were dosed with EDP1815 produced using different manufacturing processes, the
Company is evaluating drug substance produced using both manufacturing processes
in the Phase 2 atopic dermatitis trial.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses